共 8 条
[1]
Randomised phase II study of siltuximab (CNTO 328); an anti-IL-6 monoclonal antibody; in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.[J].K. Fizazi;J.S. De Bono;A. Flechon;A. Heidenreich;E. Voog;N.B. Davis;Ming Qi;R. Bandekar;J.T. Vermeulen;M. Cornfeld;G.R. Hudes.European Journal of Cancer.2011, 1
[2]
Stimulation of inflammatory gene expression in human preadipocytes by macrophage-conditioned medium: Upregulation of IL-6 production by macrophage-derived IL-1β.[J].Adrian O’Hara;Fei-Ling Lim;Dawn J. Mazzatti;Paul Trayhurn.Molecular and Cellular Endocrinology.2011, 2
[3]
[5]
[6]
[7]
[8]

